EMCURE · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 62/100 — Quality 72 · Valuation 28 · Growth 60 · Momentum 100
| Share price | ₹1,861.20 |
| Market cap | ₹27,592 Cr |
| P/E ratio | 31.7 |
| P/B ratio | 5.8 |
| ROCE | 25.1% |
| Dividend yield | 0.21% |
| Book value | ₹250.31 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹9,204 Cr | ₹941 Cr | 20.0% |
| 2025 | ₹7,896 Cr | ₹707 Cr | 19.0% |
| 2024 | ₹6,658 Cr | ₹528 Cr | 18.0% |
| 2023 | ₹5,986 Cr | ₹562 Cr | 20.0% |
| 2022 | ₹5,855 Cr | ₹703 Cr | 23.0% |
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglut